Aurobindo Pharma gets 8 observations for 2 plants from USFDA

The USFDA inspected active pharmaceutical ingredients (API) manufacturing facility (Unit V) at Pashamylaram and API manufacturing facility (Unit VIII) at Gaddapotharam in Hyderabad between October 21 and October 28, the company said in a BSE filing.

from Moneycontrol Business News https://ift.tt/2PSHuLM